Pipeline

NKMax is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer, autoimmune disease and neurodegenerative conditions.

SNK01, NKMax’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology, autoimmune disease and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Oncology

Preclinical

Phase I

Phase II

Phase III

SNK01-N12a: Stage IV Non Small Cell Lung Cancer

SNK01 + Keytruda (pembrolizumab)

Phase II

SNK01-US01: Refractory Solid Tumors

Single Agent SNK01

Phase I

SNK01-US02: Advanced/Metastatic HER2 + Solid Tumors

SNK01 + Herceptin (trastuzumab)

Preclinical

SNK01-US05: Advanced/Metastatic Osteosarcoma

Single Agent SNK01

Preclinical

SNK01-US06: Stage I-IV Triple Negative Breast Cancer

Single Agent SNK01

Preclinical

SNK01-US08: Advanced EGFR+ Solid Tumors

SNK01 + Erbitux (cetixumab)

Preclinical

SNK01-US09: Advanced Non-Hodgkin’s Lymphoma

SNK01 + Rituxin (rituximab)

Preclinical

Active
Active
In Planning
In Planning
In Planning
In Planning
In Planning

Autoimmune Diseases

Preclinical

Phase I

Phase II

Phase III

SNK01-MX03: Moderate to Severe Psoriasis

Single Agent SNK01

Phase I

SNK01-MX07: Moderate to Severe Rheumatoid Arthritis

Single Agent SNK01

Preclinical

SNK01-MX10: Moderate to Severe Multiple Sclerosis

Single Agent SNK01

Preclinical

Active
In Planning
In Planning

Neurodegenerative Diseases

Preclinical

Phase I

Phase II

Phase III

SNK01-MX04: Mild to Moderate Alzheimer’s Disease

Single Agent SNK01

Preclinical

SNK01-MX04: Mild to Moderate Alzheimer’s Disease

Single Agent SNK01

In Planning